Terms: = Lung cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Clinical Outcome
48 results:
1. Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.
Fujikawa K; Saito T; Kurose K; Kojima T; Funakoshi T; Sato E; Kakimi K; Iida S; Doki Y; Oka M; Ueda R; Wada H
PLoS One; 2023; 18(9):e0291772. PubMed ID: 37729184
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of outcome after stereotactic ablative radiotherapy of patients with metachronous lung versus primary lung cancer.
Benzaquen J; Bondiau PY; Otto J; Marquette CH; Berthet JP; Naghavi AO; Schiappa R; Hannoun-Levi JM; Padovani B; Doyen J
Radiat Oncol; 2023 Jun; 18(1):97. PubMed ID: 37287020
[TBL] [Abstract] [Full Text] [Related]
3. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
[TBL] [Abstract] [Full Text] [Related]
4. Phase II Study of Taselisib in
Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
[TBL] [Abstract] [Full Text] [Related]
5. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell lung cancer.
Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
[TBL] [Abstract] [Full Text] [Related]
6. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract] [Full Text] [Related]
7. Performance of a Machine Learning Algorithm Using Electronic Health Record Data to Identify and Estimate Survival in a Longitudinal Cohort of Patients With lung cancer.
Yuan Q; Cai T; Hong C; Du M; Johnson BE; Lanuti M; Cai T; Christiani DC
JAMA Netw Open; 2021 Jul; 4(7):e2114723. PubMed ID: 34232304
[TBL] [Abstract] [Full Text] [Related]
8. The relative biological effectiveness of carbon ion radiation therapy for early stage lung cancer.
Jeong J; Taasti VT; Jackson A; Deasy JO
Radiother Oncol; 2020 Dec; 153():265-271. PubMed ID: 32976878
[TBL] [Abstract] [Full Text] [Related]
9. Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study.
Corcoran JP; Psallidas I; Gerry S; Piccolo F; Koegelenberg CF; Saba T; Daneshvar C; Fairbairn I; Heinink R; West A; Stanton AE; Holme J; Kastelik JA; Steer H; Downer NJ; Haris M; Baker EH; Everett CF; Pepperell J; Bewick T; Yarmus L; Maldonado F; Khan B; Hart-Thomas A; Hands G; Warwick G; De Fonseka D; Hassan M; Munavvar M; Guhan A; Shahidi M; Pogson Z; Dowson L; Popowicz ND; Saba J; Ward NR; Hallifax RJ; Dobson M; Shaw R; Hedley EL; Sabia A; Robinson B; Collins GS; Davies HE; Yu LM; Miller RF; Maskell NA; Rahman NM
Eur Respir J; 2020 Nov; 56(5):. PubMed ID: 32675200
[TBL] [Abstract] [Full Text] [Related]
10. Growth and clinical Impact of 6-mm or Larger Subsolid Nodules after 5 Years of Stability at Chest CT.
Lee JH; Lim WH; Hong JH; Nam JG; Hwang EJ; Kim H; Goo JM; Park CM
Radiology; 2020 May; 295(2):448-455. PubMed ID: 32181731
[TBL] [Abstract] [Full Text] [Related]
11. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract] [Full Text] [Related]
12. Type and case volume of health care facility influences survival and surgery selection in cases with early-stage non-small cell lung cancer.
Wang S; Lai S; von Itzstein MS; Yang L; Yang DM; Zhan X; Xiao G; Halm EA; Gerber DE; Xie Y
Cancer; 2019 Dec; 125(23):4252-4259. PubMed ID: 31503336
[TBL] [Abstract] [Full Text] [Related]
13. Molecular Characterization and clinical Relevance of Metabolic Expression Subtypes in Human cancers.
Peng X; Chen Z; Farshidfar F; Xu X; Lorenzi PL; Wang Y; Cheng F; Tan L; Mojumdar K; Du D; Ge Z; Li J; Thomas GV; Birsoy K; Liu L; Zhang H; Zhao Z; Marchand C; Weinstein JN; ; Bathe OF; Liang H
Cell Rep; 2018 Apr; 23(1):255-269.e4. PubMed ID: 29617665
[TBL] [Abstract] [Full Text] [Related]
14. Treatment-Related Adverse Events Predict Improved clinical outcome in NSCLC Patients on KEYNOTE-001 at a Single Center.
Lisberg A; Tucker DA; Goldman JW; Wolf B; Carroll J; Hardy A; Morris K; Linares P; Adame C; Spiegel ML; Wells C; McKenzie J; Ledezma B; Mendenhall M; Abarca P; Bornazyan K; Hunt J; Moghadam N; Chong N; Nameth D; Marx C; Madrigal J; Vangala S; Shaverdian N; Elashoff D; Garon EB
Cancer Immunol Res; 2018 Mar; 6(3):288-294. PubMed ID: 29382669
[TBL] [Abstract] [Full Text] [Related]
15. Tracking the Evolution of Non-Small-Cell lung cancer.
Jamal-Hanjani M; Wilson GA; McGranahan N; Birkbak NJ; Watkins TBK; Veeriah S; Shafi S; Johnson DH; Mitter R; Rosenthal R; Salm M; Horswell S; Escudero M; Matthews N; Rowan A; Chambers T; Moore DA; Turajlic S; Xu H; Lee SM; Forster MD; Ahmad T; Hiley CT; Abbosh C; Falzon M; Borg E; Marafioti T; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Shah R; Joseph L; Quinn AM; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Dentro S; Taniere P; O'Sullivan B; Lowe HL; Hartley JA; Iles N; Bell H; Ngai Y; Shaw JA; Herrero J; Szallasi Z; Schwarz RF; Stewart A; Quezada SA; Le Quesne J; Van Loo P; Dive C; Hackshaw A; Swanton C;
N Engl J Med; 2017 Jun; 376(22):2109-2121. PubMed ID: 28445112
[TBL] [Abstract] [Full Text] [Related]
16. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
[TBL] [Abstract] [Full Text] [Related]
17. Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy.
Li R; Gu J; Heymach JV; Shu X; Zhao L; Han B; Ye Y; Roth J; Wu X
Carcinogenesis; 2017 Apr; 38(4):419-424. PubMed ID: 28186269
[TBL] [Abstract] [Full Text] [Related]
18. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell lung cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract] [Full Text] [Related]
19. Establishing stereotactic body radiotherapy with flattening filter free techniques in the treatment of pulmonary lesions - initial experiences from a single institution.
Rieber J; Tonndorf-Martini E; Schramm O; Rhein B; König L; Adeberg S; Meyerhof E; Mohr A; Kappes J; Hoffmann H; Debus J; Rieken S
Radiat Oncol; 2016 Jun; 11():80. PubMed ID: 27411832
[TBL] [Abstract] [Full Text] [Related]
20. Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.
Meerang M; Bérard K; Friess M; Bitanihirwe BK; Soltermann A; Vrugt B; Felley-Bosco E; Bueno R; Richards WG; Seifert B; Stahel R; Weder W; Opitz I
Mol Oncol; 2016 Oct; 10(8):1255-65. PubMed ID: 27378628
[TBL] [Abstract] [Full Text] [Related]
[Next]
